Share chart Spyre Therapeutics, Inc.
Extended chart
Simple chart
About
Spyre Therapeutics, Inc., биотехнологическая компания, специализируется на продвижении линейки терапевтических средств на основе антител для лечения воспалительных заболеваний кишечника путем объединения инженерии антител, рациональных терапевтических комбинаций и прецизионных медицинских подходов к отбору пациентов. В портфолио компании входят антитела с увеличенным периодом полураспада, нацеленные на a4β7, TL1A и IL-23. Компания ранее была известна как Aeglea BioTherapeutics, Inc. и сменила название на Spyre Therapeutics, Inc. в ноябре 2023 года. Spyre Therapeutics, Inc. more details| IPO date | 2016-04-07 |
|---|---|
| ISIN | US00773J2024 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.spyre.com |
| Цена ао | 35.99 |
| Change price per day: | -1.66% (24.07) |
|---|---|
| Change price per week: | -0.7963% (23.86) |
| Change price per month: | -14.7% (27.75) |
| Change price per 3 month: | -16.92% (28.49) |
| Change price per half year: | -0.5044% (23.79) |
| Change price per year: | +9.99% (21.52) |
| Change price per 3 year: | +536.29% (3.72) |
| Change price per 5 year: | +202.3% (7.83) |
| Change price per 10 year: | -0% (23.67) |
| Change price per year to date: | -12.59% (27.08) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Driehaus Capital Management, LLC | 800853 | 19.78 |
| Franklin Resources, Inc. | 687090 | 16.97 |
| Fairmount Funds Management LLC | 378421 | 9.35 |
| Polar Capital Holdings PLC | 300000 | 7.41 |
| Wellington Management Group, LLP | 299929 | 7.41 |
| VR Adviser, LLC | 295034 | 7.29 |
| Affinity Asset Advisors, LLC | 242297 | 5.98 |
| Logos Global Management LP | 210000 | 5.19 |
| EcoR1 Capital, LLC | 199996 | 4.94 |
| Suvretta Capital Management, LLC | 162395 | 4.01 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares Morningstar Small-Cap Value ETF | 0.02406 | 199.14 | 2.50476 |
| iShares Morningstar Small Cap Value ETF | 0.02406 | 26.7 | 2.50476 |
| iShares Morningstar Small-Cap ETF | 0.02198 | 391.25 | 1.60498 |
| iShares Morningstar Small-Cap ETF | 0.02198 | 30.1 | 1.60498 |
| iShares Morningstar Small-Cap Growth ETF | 0.02 | 33.63 | 0.72598 |
| iShares Morningstar Small-Cap Growth ETF | 0.02 | 590.83 | 0.72598 |
iShares Russell 2000 Growth ETF
|
0.00646 | 38.04 | 0.6026 |
| iShares Russell 3000 ETF | 0.00187 | 23.61 | 1.43482 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Cameron Turtle DPHIL, Ph.D. | CEO & Director | 674.17k | 1990 (35 years) |
| Mr. Scott L. Burrows | Chief Financial Officer | 331.81k | 1977 (48 years) |
| Dr. Janet Gunzner-Toste M.B.A., Ph.D. | Senior Vice President of Operations | N/A | |
| Mr. Eric McIntyre | Vice President of Finance & Investor Relations | N/A | |
| Ms. Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer & Corporate Secretary | 568.87k | 1983 (42 years) |
| Mr. James Myers | Vice President of Quality & Compliance | N/A | |
| Dr. Kelly Boothe Ph.D. | Senior Director of Corporate Communications & Investor Relations | N/A | |
| Dr. Justin LaFountaine Ph.D. | Senior Vice President of Corporate Development | N/A | |
| Mr. Brian Connolly | Chief Technical Officer | N/A | |
| Ms. Melissa Cooper | Senior Vice President of People | N/A |
Address: United States, Waltham. MA, 221 Crescent Street - open in Google maps, open in Yandex maps
Website: https://www.spyre.com
Website: https://www.spyre.com
